Trial intelligence / Profile preview

Clonidine for Postoperative Pain in Endometriosis Surgery

NCT05560230Phase 4

Key facts

Status: Completed
Start: Oct 2022
Primary completion: Aug 2024
Countries: 1
Sponsor: Aarhus University
Modality: Small Molecules

Drugs: clonidine
Conditions: postoperative pain

Overview

Phase 4, randomised, double-blind trial in postoperative pain comparing Clonidine with Placebo (2 arms). Primary endpoint: Cumulative opioid consumption 0-3 hours. Started Oct 2022; status: completed.

Design

2 arms

Study design: RandomizedDouble-blind

Clonidine
Clonidine 150 mcg IV
Placebo
Isotonic saline IV

Who it enrols

Patients scheduled for surgical laparoscopic treatment of endometriosis. Excludes daily opioid consumption, severe renal insufficiency, severe bradyarrhythmia, and chronic pain > 5/10.

Endpoints

Primary

Cumulative opioid consumption 0-3 hours3 hours

Secondary

Cumulative opioid consumption 0-6 hours6 hours
Pain intensity at rest120 months
Pain intensity during coughing120 months
Shivering120 months
Sedation (Ramsey Sedation Score)120 months
Postoperative Nausea and Vomiting120 months
Discharge from the PACU24 hours

Beyond the preview

Go deeper on NCT05560230.

Full results, competitive context and analysis are in the Gosset platform.

Full results & analysis

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT05560230.